Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study
Conference abstract
[키워드] Activation
active cancer
administration
Against
antibody
assessment
Biomarker
Blood
blood sample
BNT162b2
BNT162b2 vaccine
calculated
centrifugation
collected
conducted
Control
control group
controls
COVID-19
COVID-19 vaccine
E-selectin
Effect
endothelial
Endothelial cell
Endothelium
Evidence
expected
Factor
first dose
France
funding
FVIII
groups
Health
Health care worker
Hospital admission
Host
hypercoagulability
immune response
individual
inflammatory reaction
inhibitor
Injury
less
limit
Mild
MRI
mRNA
mRNA vaccines
no difference
not significantly different
of BNT162b2
pathway
Patient
Patients with cancer
peak
PF4
Pfizer/BioNTech
plasma
Platelet
platelet activation
Prevent
Probably
procoagulant
Prospective
prospective observational study
provoke
raised
reported
resulting
risk
Sample
severe disease
shown
significantly higher
significantly increased
stratified
subject
Support
symptomatic infection
temperature
TFPI
the spike protein
thrombin
thrombosis
thrombotic complication
thrombotic event
tissue
triggered
UNL
vaccinated individual
vaccinated individuals
vaccination
Vaccine
Vaccines
Venous thrombosis
virus
von Willebrand factor
were assessed
worker
[DOI] 10.1182/blood-2021-146803 [Article Type] Conference abstract
[DOI] 10.1182/blood-2021-146803 [Article Type] Conference abstract